Dr Chaudhuri has been an operating partner at Frazier Healthcare since 2011, focusing on investments in later-stage companies and in international opportunities. Prior to joining Frazier, he was president of Valeant Pharmaceuticals (currently Bausch Health), where he led Valeant’s international operations and business development activities. He joined Valeant through its acquisition of Dow Pharmaceutical Sciences, where he had been president and CEO. Dow focused on dermatology drug development and commercialization and was the source of multiple approved products. Before Dow, Bhaskar worked at Mylan Pharmaceuticals in several capacities including EVP of scientific affairs at Mylan subsidiary Bertek Pharmaceuticals, and as general manager of the dermatology division. Earlier, he worked at Penederm as VP of R&D. In addition to Arcutis, he also serves on the board of Silvergate Pharmaceuticals (private) and Teligent (NASDAQ: TLGT). He also serves on the advisory board of the Johns Hopkins Berman Institute of Bioethics. He holds a PhD from the University of Louisiana, and an MS and a BS in pharmacy from Jadavpur University, India.